文献速递糖尿病

低剂量螺内酯治疗2型糖尿病合并慢性肾脏病的疗效与安全性

Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项多中心、开放标签、随机对照试验纳入130例日本2型糖尿病伴白蛋白尿患者,评估每日12.5 mg螺内酯治疗24周对尿白蛋白肌酐比(UACR)的影响。结果显示螺内酯组UACR较基线平均下降103.47±340.80 mg/gCre,对照组平均升高63.93±310.14 mg/gCre(P=0.0007);螺内酯组血钾有统计学显著升高,但24周时无受试者血钾≥5.5 mEq/L。结论认为低剂量螺内酯可减少白蛋白尿且不引起高钾血症。

要点

  • 螺内酯组UACR较基线平均下降103.47±340.80 mg/gCre,对照组平均升高63.93±310.14 mg/gCre(P=0.0007)。
  • 螺内酯组血钾有统计学显著升高,但24周时无受试者血钾≥5.5 mEq/L。
  • 基线血钾较高的受试者血钾升幅趋向更小(估计值-0.37,协方差分析)。

核心结论

  • 低剂量螺内酯(12.5 mg/d)给药可减少白蛋白尿且不引起高钾血症。
  • 作者认为,作为已知最古老且最具成本效益的盐皮质激素受体拮抗剂,螺内酯应以较低剂量重新考虑使用。

研究设计与样本

  • 多中心、开放标签、随机对照试验。
  • 研究于2016年7月至2020年11月在日本3家糖尿病医疗机构门诊开展。
  • 纳入130例日本2型糖尿病伴白蛋白尿(≥30 mg/gCre)、估算肾小球滤过率≥30 mL/min/1.73 m²且血清钾<5.0 mEq/L的成人患者。
  • 受试者被随机分配至螺内酯给药组和对照组。
  • 主要结局指标为24周干预期间UACR较基线的变化。

主要发现

  • 螺内酯组UACR较基线显著下降(平均下降103.47±340.80 mg/gCre),对照组UACR升高(平均升高63.93±310.14 mg/gCre;P=0.0007,Wilcoxon秩和检验和t检验)。
  • 螺内酯组血清钾水平有统计学显著升高,但24周时无受试者血钾≥5.5 mEq/L。
  • 基线血清钾较高的受试者血钾升幅趋向更小(估计值-0.37,协方差分析)。

关键数值与推荐

  • 螺内酯剂量为12.5 mg/d。
  • 纳入标准:白蛋白尿≥30 mg/gCre,估算肾小球滤过率≥30 mL/min/1.73 m²,血清钾<5.0 mEq/L。
  • 主要结局为24周干预期间UACR较基线的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although adding spironolactone to renin-angiotensin system blockers reduces albuminuria in adults with chronic kidney disease and type 2 diabetes, it increases the risk of hyperkalemia. OBJECTIVE: To assess whether a lower dose of spironolactone (12.5 mg/d) reduces the risk of hyperkalemia while maintaining its effect on reducing albuminemia. DESIGN: Multicenter, open-label, randomized controlled trial. SETTING: This study was conducted from July 2016 to November 2020 in ambulatory care at 3 diabetes medical institutions in Japan. PATIENTS: We enrolled 130 Japanese adults with type 2 diabetes and albuminuria (≥30 mg/gCre), estimated glomerular filtration rate ≥30 mL/min/1.73 m2, and serum potassium level <5.0 mEq/L. INTERVENTIONS: The participants were randomly assigned to the spironolactone-administered and control groups. MAIN OUTCOME MEASURES: Changes in urine albumin-to-creatinine ratio (UACR) from baseline over the 24-week interventional period. RESULTS: The spironolactone group showed a significant reduction in UACR from baseline (mean decrease, 103.47 ± 340.80 mg/gCre) compared with the control group, which showed an increased UACR (mean increase, 63.93 ± 310.14 mg/gCre; P = .0007, Wilcoxon rank-sum test and t test). Although the spironolactone group had a statistically significant increase in serum potassium levels, none of the participants had a potassium level ≥5.5 mEq/L at 24 weeks. Further, participants with a higher initial serum potassium level tended to have a smaller increase (estimate, -0.37, analysis of covariance). CONCLUSIONS: Low-dose spironolactone administration reduced albuminuria without causing hyperkalemia. Spironolactone administration, the oldest known and most cost-effective mineralocorticoid receptor antagonist, at lower doses should be reconsidered.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Oiwa A, Hiwatashi D, Takeda T, et al. Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 36916985. doi:10.1210/clinem/dgad144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。